AmyTrap-3
Alzheimer's Disease
PreclinicalActive
Key Facts
About Recombinant Technologies
Recombinant Technologies is an emerging biotech firm developing the AmyTrap platform, a proprietary approach to sequester and remove toxic beta-amyloid as a treatment for Alzheimer's disease and related beta-amyloidopathies. The company's lead asset, AmyTrap-3, is a small molecule queued for IND-enabling studies, supported by proof-of-concept data and multiple NIH SBIR grants. RTL is privately funded, pre-revenue, and operates out of New Haven, Connecticut, with a vision to expand its technology to other neurodegenerative indications.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |